PMID- 35285490
OWN - NLM
STAT- MEDLINE
DCOM- 20220610
LR  - 20240102
IS  - 1549-490X (Electronic)
IS  - 1083-7159 (Print)
IS  - 1083-7159 (Linking)
VI  - 27
IP  - 6
DP  - 2022 Jun 8
TI  - Impact of the COVID-19 Pandemic on Management of Patients with Metastatic 
      Pancreatic Ductal Adenocarcinoma in the United States.
PG  - e518-e523
LID - 10.1093/oncolo/oyac029 [doi]
AB  - BACKGROUND: The purpose of this study was to understand how the COVID-19 pandemic 
      has affected health care patterns and outcomes for patients diagnosed with 
      metastatic pancreatic ductal adenocarcinoma (mPDAC) in 2020 compared with those 
      diagnosed with mPDAC in 2019. PATIENTS AND METHODS: We used the Flatiron Health 
      database to identify adults diagnosed with mPDAC from March 1 to September 30, 
      2019 (pre-COVID-19 cohort) and March 1 to September 30, 2020 (post-COVID-19 
      cohort). Between-cohort comparisons included demographic and clinical 
      characteristics and year-over-year data for diagnosis of mPDAC, newly treated 
      patients, time to and types of first-line therapy, and adverse events (AEs) 
      during first-line therapy. Overall survival (OS) and milestone survival rates 
      were evaluated. Kaplan-Meier methods were used to assess OS. RESULTS: 
      Pre-COVID-19 (n = 923) and post-COVID-19 (n = 796) cohorts had similar baseline 
      demographic characteristics. A smaller proportion of patients in the pre-COVID-19 
      cohort were initially diagnosed with stage IV disease versus the post-COVID-19 
      cohort (62.2% vs 69.7%). Between 2019 and 2020, there was a 13.8% decrease in 
      diagnosis of mPDAC and a 13.0% decrease in newly treated patients. Median 
      (interquartile range) times to first-line treatment were similar (21 [13-40] and 
      19 [12-32] days). Median OS (months) was significantly longer in the pre-COVID-19 
      cohort (8.4 [95% CI: 7.5, 9.0]) versus the post-COVID-19 cohort (6.1 [95% CI: 
      5.4, 6.9]; P < .001). Survival rates were higher in the pre-COVID-19 versus 
      post-COVID-19 cohorts. CONCLUSIONS: During the pandemic, patients were initially 
      diagnosed with PDAC at more advanced stages. While patients in both cohorts 
      appeared to receive similar care, survival outcomes were adversely affected.
CI  - (c) The Author(s) 2022. Published by Oxford University Press.
FAU - Paluri, Ravi
AU  - Paluri R
AUID- ORCID: 0000-0002-2317-7082
AD  - Wake Forest Baptist Health, Winston-Salem, NC, USA.
FAU - Laursen, Ashley
AU  - Laursen A
AD  - Ipsen, Cambridge, MA, USA.
FAU - Gaeta, Joseph
AU  - Gaeta J
AD  - Ipsen, Cambridge, MA, USA.
FAU - Wang, Shu
AU  - Wang S
AD  - Genesis Research, Hoboken, NJ, USA.
FAU - Surinach, Andy
AU  - Surinach A
AUID- ORCID: 0000-0002-0743-7219
AD  - Genesis Research, Hoboken, NJ, USA.
FAU - Cockrum, Paul
AU  - Cockrum P
AD  - Ipsen, Cambridge, MA, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Oncologist
JT  - The oncologist
JID - 9607837
SB  - IM
MH  - *Adenocarcinoma/pathology
MH  - Adult
MH  - *COVID-19
MH  - *Carcinoma, Pancreatic Ductal/pathology
MH  - Humans
MH  - *Pancreatic Neoplasms/drug therapy/therapy
MH  - Pandemics
MH  - Retrospective Studies
MH  - United States/epidemiology
PMC - PMC9177109
OTO - NOTNLM
OT  - COVID-19
OT  - metastatic pancreatic ductal adenocarcinomam
OT  - overall survival
OT  - treatment patterns
EDAT- 2022/03/15 06:00
MHDA- 2022/06/11 06:00
PMCR- 2022/03/14
CRDT- 2022/03/14 08:42
PHST- 2021/08/18 00:00 [received]
PHST- 2021/12/31 00:00 [accepted]
PHST- 2022/03/15 06:00 [pubmed]
PHST- 2022/06/11 06:00 [medline]
PHST- 2022/03/14 08:42 [entrez]
PHST- 2022/03/14 00:00 [pmc-release]
AID - 6548145 [pii]
AID - oyac029 [pii]
AID - 10.1093/oncolo/oyac029 [doi]
PST - ppublish
SO  - Oncologist. 2022 Jun 8;27(6):e518-e523. doi: 10.1093/oncolo/oyac029.